Ace Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual Meeting
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc. (“AVG” or “the Company”), an emerging medical device company on the forefront of pioneering a laser microporation therapy for the aging eye, today announced that it will host an event and multiple scientific presentations at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 25-28, 2025 in Los Angeles, California.
These presentations will showcase the company’s latest clinical advancements and novel research in laser scleral microporation – a minimally invasive treatment designed to restore natural Dynamic Range of Focus (DRoF) in presbyopic patients. The company’s participation highlights its continued leadership in the development of non-lens-based solutions for aging-related vision loss.
Explore More Articles
The Future of the Aging Eye
AnnMarie Hipsley, the Founder and CEO of Ace Vision Group (AVG), a Delaware, USA- based company developing innovative therapeutics for age-related ocular dysfunctions, talks to The Ophthalmologist about her background and work with AVG, and the company’s short- and long-term goals. She explains how the Group has utilized artificial intelligence and virtual reality platforms to …
Show videoVIDEO: New laser offers further improvement to laser scleral microporation
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, AnnMarie Hipsley, DPT, PhD, and George O. Waring IV, MD, FACS, discuss the latest advances in laser scleral microporation.Hipsley said that the GenII VisioLite laser for laser scleral microporation (LSM) is on the pathway to commercialization and may be available by the end of the year.
read moreLaser scleral microporation may solve biomechanical problem of presbyopia
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Lopez of Ace Vision Group discusses laser scleral microporation for presbyopia. Lopez said the GenII device can potentially deliver improved near vision without compromising distance vision in patients with presbyopia. The company plans to do a study in the United States in 2026, potentially leading to commercial availability in …
read more